Dr. Jungen, former head of M&A for DZ Bank, will share his insights on the cannabis market in Germany, and detail the opportunities for investment in this emerging industry.
CEO EPC HEALTHCARE GmbH
FOUNDER OF KRAUTINVEST.DE
FOUNDER AND MANAGING DIRECTOR OF SANITY GROUP, MD
Germany is the biggest medical cannabis market in Europe. Our panel of successful German entrepreneurs will give an overview of the structure of the market and its current status. What factors will dominate market growth? What strategies are being employed to most efficiently capitalize on this burgeoning industry. How is the market set to change over the next 5 years?
Investors are eager to enter the global cannabis market that is projected to reach over 100 billion USD by the end of 2026. Investment enthusiasm must be tempered by calculated planning and awareness of the inherent risks in the public and private sectors of this rapidly evolving market. As the expansion of the EU market resumes in the wake of the pandemic, the opportunities are surging, with some on the trajectory towards significant global impact. It’s crucial to learn from the successes and failures of the U.S. and Canadian markets and strategically place future investments in companies that are positioned to be global leaders and successful investments.
In this session, Nic Easley, CEO of 3C Consulting and Managing Director of Multiverse Capital, will walk both entrepreneurs and investors through how to plan for and determine the best current and future global opportunities. Topics will include a global industry overview, investing in public vs. private markets and the risks associated with this agricultural and consumer packaged goods start-up industry. Nic will share his insights and experience from the operational and investment sides of the cannabis industry to educate all on the dos and don'ts from the cannabis trenches and how to create successful businesses and investments for years to come.
PARTNER, DENTONS • HEAD OF EUROPEAN CANNABIS GROUP
KFN+ LAW OFFICE, FOUNDER
MEDICAL CANNABIS CONSULTANT, ALEXANDER RIEG PHARMA CONSULTING
Regulatory compliance is increasingly a financial conversation first. Beyond "recreational reform" or "lifestyle" labels, the global industry is beginning to use pharmaceutical and more formal processes and terminology as well as compliance standards for both the plant and its components - no matter what part of the market the company operates or plans to operate in. Understand from the experts what is required and what is just window dressing. GACP vs GMP is just the beginning. One thing is for sure. A cannabis business plan with no formal compliance line items and process plan is just a pile of paper with cannabis involved.
CONSULTANT, HANWAY ASSOCIATES
MB & PARTNER, ZURICH UND MOSER CONSULTING, GÜGLINGEN
VICE PRESIDENT OF INVESTMENT ANALYSIS, SEED INNOVATIONS
CHIEF FINANCIAL OFFICER, CANADELAAR
Learn from the pioneers who have paid their dues - and closed the deal! Understand what regulations count - and which can destroy ROI from the get go. Also get a perspective on how to evaluate country-specific certifications and understand what else might be needed for cross border sales (in both adult use and medical markets). Finally, get a first look at how economic incentives and tax incentives across Europe can increasingly be used to co-finance certified and regulated cannabis projects.
Get ready for a fast and furious pitch session with a wide array of companies hand-picked by the ICBC.
Network hands-on and directly with the featured companies at their respective pitch tables, as well as network with other conference attendees in an elegant and relaxed atmosphere with open-bar.